Register now for a personalized educational experience.
Already a member? Log In
By linking my Doximity account with UPMC Physician Resources, I acknowledge that:
Forgot your password? Enter the email address you used to create your account to initiate a password reset.
Dr. Stephanie Maximous provides a pulmonary and critical care medicine update and reviews inhaled triple therapy for COPD patients, endobronchial valves, and immunotherapy treatment in lung cancer. Dr. Maximous also describes limitations of the studies evaluating vitamin C and crystalloids in septic shock patients.
Upon completion of this activity, participants should be able to:
Dr. Stephanie Maximous has reported no relevant relationships with entities producing health care goods or services.
The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Pittsburgh School of Medicine designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits. Each physician should only claim credit commensurate with the extent of their participation in the activity. Other health care professionals are awarded (.075) continuing education units (CEU) which are equivalent to .75 contact hour.
For your credit transcript, please access our website 4 weeks post-completion at http://ccehs.upmc.com and follow the link to the Credit Transcript page. If you do not provide the last 5 digits of your SSN on the next page you will not be able to access a CME credit transcript. Providing your SSN is voluntary.
ABIM MOC Part 2 Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive your ABIM MOC Part 2 credit, you will need to complete the post-test with a pass rate of 100% and provide your date of birth and ABIM number, along with the other required fields. This information will be shared with the American Board of Internal Medicine using the Accreditation Council for Continuing Medical Education Program and Activity Reporting System.
Release Date: 4/25/2019 | Last Modified On: 4/25/2019 | Expires: 4/27/2020
1.Antonia et al. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. N Engl J Med 2017; 377:1919-1929.
2.Antonia et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med 2018; 379:2342-2350.
3.Marik et al. Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock. Chest 2017; 151:1229-38.
4.Pillai et al. Comparison of the Toxicity Profile of PD-1 versus PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Analysis of the Literature. Cancer 2018; 124:271-77.
5.Self et al. Balanced crystalloids versus saline in noncritically ill adults. N Engl J Med 2018. 378:819-828.
6.Semler et al. Balanced Crystalloids versus Saline in Critically Ill Adults. N Engl J Med 2018; 378:829-839.
7.Sgro. Bring Yourself to Work. Journal of Graduate Medical Education 2018; 10:230-31.
8.Soria et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2018; 378:113-125.
9.Thomson et al. Addressing Gender Inequality in Our Disciplines: Report from the Association of Pulmonary, Critical Care, and Sleep Division Chiefs. Ann Am Thorac Soc 2018; 15:1382–90.
10.Vestbo et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomized controlled trial. Lancet 2017; 389: 1919-29.